HK1208024A1 - Substituted thiophene- and furan-fused azolopyrimidine-5-(6h)-one compounds -5-(6h)- - Google Patents

Substituted thiophene- and furan-fused azolopyrimidine-5-(6h)-one compounds -5-(6h)-

Info

Publication number
HK1208024A1
HK1208024A1 HK15108624.0A HK15108624A HK1208024A1 HK 1208024 A1 HK1208024 A1 HK 1208024A1 HK 15108624 A HK15108624 A HK 15108624A HK 1208024 A1 HK1208024 A1 HK 1208024A1
Authority
HK
Hong Kong
Prior art keywords
azolopyrimidine
furan
fused
compounds
substituted thiophene
Prior art date
Application number
HK15108624.0A
Other languages
English (en)
Chinese (zh)
Inventor
Bryan Branstetter
Brian Dyck
Laurent Gomez
Andrew Richard Hudson
Tami Jo Marrone
Troy Vickers
Marco Peters
James Breitenbucher
Original Assignee
Dart Neuroscience Cayman Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dart Neuroscience Cayman Ltd filed Critical Dart Neuroscience Cayman Ltd
Publication of HK1208024A1 publication Critical patent/HK1208024A1/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D495/14—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5386—1,4-Oxazines, e.g. morpholine spiro-condensed or forming part of bridged ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/541—Non-condensed thiazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/14—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
    • C07D487/14—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/22—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains four or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems
    • C07D491/107—Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/12—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains three hetero rings
    • C07D491/14—Ortho-condensed systems
    • C07D491/147—Ortho-condensed systems the condensed system containing one ring with oxygen as ring hetero atom and two rings with nitrogen as ring hetero atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/22—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains four or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/22—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains four or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/08—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
HK15108624.0A 2012-06-18 2015-09-02 Substituted thiophene- and furan-fused azolopyrimidine-5-(6h)-one compounds -5-(6h)- HK1208024A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261661091P 2012-06-18 2012-06-18
PCT/US2013/046403 WO2013192225A1 (en) 2012-06-18 2013-06-18 Substituted thiophene- and furan-fused azolopyrimidine-5-(6h)-one compounds

Publications (1)

Publication Number Publication Date
HK1208024A1 true HK1208024A1 (en) 2016-02-19

Family

ID=49756458

Family Applications (2)

Application Number Title Priority Date Filing Date
HK15108586.6A HK1208023A1 (en) 2012-06-18 2015-09-02 Substituted pyridine azolopyrimidine-5-(6h)-one compounds -5-(6h)-
HK15108624.0A HK1208024A1 (en) 2012-06-18 2015-09-02 Substituted thiophene- and furan-fused azolopyrimidine-5-(6h)-one compounds -5-(6h)-

Family Applications Before (1)

Application Number Title Priority Date Filing Date
HK15108586.6A HK1208023A1 (en) 2012-06-18 2015-09-02 Substituted pyridine azolopyrimidine-5-(6h)-one compounds -5-(6h)-

Country Status (18)

Country Link
US (7) US9499562B2 (xx)
EP (3) EP2861605B1 (xx)
JP (2) JP6129960B2 (xx)
KR (2) KR102087756B1 (xx)
CN (2) CN104583217B (xx)
AU (3) AU2013277294C1 (xx)
BR (2) BR112014031730B1 (xx)
CA (2) CA2877149C (xx)
DK (2) DK2861603T3 (xx)
ES (2) ES2715325T3 (xx)
HK (2) HK1208023A1 (xx)
IL (2) IL236232A (xx)
IN (2) IN2015DN00335A (xx)
MX (2) MX359615B (xx)
NZ (2) NZ703949A (xx)
RU (2) RU2653054C2 (xx)
SG (3) SG10201703253XA (xx)
WO (2) WO2013192229A1 (xx)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2305353A1 (en) * 2000-08-10 2011-04-06 Cold Spring Harbor Laboratory Augmented cognitive training
BR112014031730B1 (pt) * 2012-06-18 2023-05-16 Dart Neuroscience (Cayman) Ltd Compostos ou sais farmaceuticamente aceitáveis dos mesmos e seu uso
JP6396230B2 (ja) * 2014-01-27 2018-09-26 株式会社ポーラファルマ 使用時泡状を呈する外用医薬組成物
JP6396229B2 (ja) * 2014-01-27 2018-09-26 株式会社ポーラファルマ 使用時泡状を呈する外用医薬組成物
JP6396231B2 (ja) * 2014-01-27 2018-09-26 株式会社ポーラファルマ 使用時泡状を呈する外用医薬組成物
GB201406486D0 (en) * 2014-04-10 2014-05-28 Redx Pharma Ltd Antibacterial compounds
TW201629064A (zh) 2014-10-10 2016-08-16 Ｈ 朗德貝克公司 作爲ｐｄｅ１抑制劑之三唑並吡酮
JO3627B1 (ar) 2015-04-30 2020-08-27 H Lundbeck As إيميدازو بيرازينونات على هيئة مثبطات pde1
WO2017046603A1 (en) * 2015-09-18 2017-03-23 Redx Pharma Plc Antibacterial compounds and new uses thereof
AR107456A1 (es) 2016-02-12 2018-05-02 Lilly Co Eli Inhibidor de pde1
TWI729109B (zh) 2016-04-12 2021-06-01 丹麥商Ｈ 朗德貝克公司 作爲PDE1抑制劑的1,5-二氫-4H-吡唑并[3,4-d]嘧啶-4-酮和1,5-二氫-4H-吡唑并[4,3-c]吡啶-4-酮
JOP20170164A1 (ar) 2016-08-25 2019-01-30 Lilly Co Eli مشتق ترايازولو بيرازينون مفيد كمثبط لـ pde1 بشري
CN109843884B (zh) * 2016-10-18 2022-03-04 H.隆德贝克有限公司 作为pde1抑制剂的咪唑并吡嗪酮、吡唑并嘧啶酮和吡唑并吡啶酮
US10912773B2 (en) 2016-10-28 2021-02-09 H. Lundbeck A/S Combinations comprising substituted imidazo[1,5-a]pyrazinones as PDE1 inhibitors
AU2017350473A1 (en) 2016-10-28 2019-04-18 H. Lundbeck A/S Combination treatments comprising imidazopyrazinones for the treatment of psychiatric and/or cognitive disorders
JP7111720B2 (ja) 2016-12-28 2022-08-02 ダート・ニューロサイエンス・エルエルシー Ｐｄｅ２阻害剤としての置換ピラゾロピリミジノン化合物
WO2018125746A1 (en) * 2016-12-30 2018-07-05 Frequency Therapeutics, Inc. 1h-pyrrole-2,5-dione compounds and methods of using them to induce self-renewal of stem/progenitor supporting cells
US10919898B2 (en) * 2017-02-23 2021-02-16 Boehringer Ingelheim International Gmbh Medical use of compound III
AR112457A1 (es) 2017-08-02 2019-10-30 Lilly Co Eli Derivados de [1,2,4]triazolo[4,3-a]pirazin-6(5h)-ona
AR112346A1 (es) 2017-08-10 2019-10-16 Lilly Co Eli Derivados de [1,2,4]triazolo
DK3717488T3 (da) 2017-11-27 2021-12-13 Dart Neuroscience Llc Substituerede furanopyrimidinforbindelser som pde1-inhibitorer
GB2575490A (en) * 2018-07-12 2020-01-15 Recordati Ind Chimica E Farmaceutica Spa P2X3 receptor antagonists
EP4017858A4 (en) * 2019-08-22 2023-09-27 Intra-Cellular Therapies, Inc. ORGANIC COMPOUNDS
CN112778311A (zh) * 2019-11-01 2021-05-11 上海翰森生物医药科技有限公司 含氮并环类衍生物抑制剂、其制备方法和应用

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3046366A1 (de) * 1980-12-09 1982-07-08 Bayer Ag, 5090 Leverkusen Tricyclische cytosinderivate zur verwendung in arzneimitteln und verfahren zu ihrer herstellung
DE3146599A1 (de) 1981-11-25 1983-07-07 Basf Ag, 6700 Ludwigshafen Neue triazolochinazoline, verfahren zu ihrer herstellung und diese enthaltende pharmazeutische zubereitungen
EP0181282A1 (de) 1984-10-01 1986-05-14 Ciba-Geigy Ag Triazolochinazolinverbindungen
EP0217748B1 (en) 1985-09-30 1991-02-06 Ciba-Geigy Ag 2-Substituted-e-fused-[1,2,4,]triazolo-[1,5-c]pyrimidines pharmaceutical compositions and uses thereof
JPS62135475A (ja) * 1985-09-30 1987-06-18 チバ−ガイギ−　アクチエンゲゼルシヤフト ２−置換−ｅ−融合−〔１，２，４〕トリアゾロ−〔１，５−Ｃ〕ピリミジン
US4938949A (en) 1988-09-12 1990-07-03 University Of New York Treatment of damaged bone marrow and dosage units therefor
FR2659329B1 (fr) 1990-03-09 1994-06-03 Adir Nouveaux derives d'imidazo [1,2-c] quinazoline, leur procede de preparation et les compositions pharmaceutiques les renfermant.
WO1999038504A1 (en) * 1998-01-29 1999-08-05 Sepracor Inc. Pharmaceutical uses of optically pure (-)-bupropion
ES2166270B1 (es) 1999-07-27 2003-04-01 Almirall Prodesfarma Sa Derivados de 8-fenil-6,9-dihidro-(1,2,4,)triazolo(3,4-i)purin-5-ona.
DE10012373A1 (de) * 2000-03-14 2001-09-20 Dresden Arzneimittel Verwendung von Pyrido[3,2-e]-pyrazinonen als Inhibitoren der Phosphodiesterase 5 zur Therapie von erektiler Dysfunktion
US8153646B2 (en) 2000-08-10 2012-04-10 Dart Neuroscience (Cayman) Ltd. Phosphodiesterase 4 inhibitors for cognitive and motor rehabilitation
US7868015B2 (en) 2000-08-10 2011-01-11 Cold Spring Harbor Laboratory Phosphodiesesterase 4 inhibitors for the treatment of a cognitive deficit
EP2305353A1 (en) 2000-08-10 2011-04-06 Cold Spring Harbor Laboratory Augmented cognitive training
FR2897061B1 (fr) * 2006-02-03 2010-09-03 Sanofi Aventis Derives de n-heteroaryl-carboxamides tricycliques contenant un motif benzimidazole, leur preparation et leur application en therapeutique.
EP2023729B1 (en) * 2006-06-06 2016-05-04 Intra-Cellular Therapies, Inc. Organic compounds
WO2008118414A1 (en) * 2007-03-28 2008-10-02 Merck & Co., Inc. Substituted pyrido[3,2-e][1,2,4]triazolo[4,3-c]pyrimidine derivatives as cannabinoid-1 receptor modulators
EP2152275A4 (en) 2007-05-15 2011-08-03 Helicon Therapeutics Inc METHODS OF IDENTIFYING GENES INVOLVED IN MEMORY FORMATION USING SMALL INTERFERING RNA (SIARN)
JP5265687B2 (ja) * 2007-09-26 2013-08-14 ジーイー・ヘルスケア・バイオサイエンス・バイオプロセス・コーポレイション 三次元の使い捨てバイオリアクター
CA2845454C (en) 2007-12-06 2017-02-07 Takeda Pharmaceutical Company Limited Organic compounds useful as inhibitors of phosphodiesterase 1
AU2008345225A1 (en) 2007-12-21 2009-07-09 University Of Rochester Method for altering the lifespan of eukaryotic organisms
KR20110095881A (ko) 2008-12-06 2011-08-25 인트라-셀룰라 써래피스, 인코퍼레이티드. 유기 화합물
WO2010065153A1 (en) 2008-12-06 2010-06-10 Intra-Cellular Therapies, Inc. Organic compounds
US11464781B2 (en) 2009-02-25 2022-10-11 Intra-Cellular Therapies, Inc. PDE1 inhibitors for ophthalmic disorders
JP2012526810A (ja) 2009-05-13 2012-11-01 イントラ−セルラー・セラピーズ・インコーポレイテッド 有機化合物
TW201206937A (en) 2010-05-31 2012-02-16 Intra Cellular Therapies Inc Organic compounds
WO2011153136A1 (en) 2010-05-31 2011-12-08 Intra-Cellular Therapies, Inc. Organic compounds
WO2011153135A1 (en) 2010-05-31 2011-12-08 Intra-Cellular Therapies, Inc. Organic compounds
WO2011153138A1 (en) * 2010-05-31 2011-12-08 Intra-Cellular Therapies, Inc. Organic compounds
US10561656B2 (en) 2011-06-10 2020-02-18 Intra-Cellular Therapies, Inc. Organic compounds
BR112014031730B1 (pt) * 2012-06-18 2023-05-16 Dart Neuroscience (Cayman) Ltd Compostos ou sais farmaceuticamente aceitáveis dos mesmos e seu uso

Also Published As

Publication number Publication date
EP2861603A4 (en) 2015-11-11
DK3489238T3 (da) 2022-01-10
BR112014031731B1 (pt) 2022-12-06
SG11201408395WA (en) 2015-01-29
US20190046535A1 (en) 2019-02-14
AU2013277294C1 (en) 2018-02-08
US10092575B2 (en) 2018-10-09
IL236232A (en) 2016-10-31
JP6129960B2 (ja) 2017-05-17
EP2861605B1 (en) 2017-05-03
WO2013192229A1 (en) 2013-12-27
SG11201408397SA (en) 2015-01-29
EP2861603A1 (en) 2015-04-22
MX357320B (es) 2018-07-04
IL236232A0 (en) 2015-02-01
JP2015526395A (ja) 2015-09-10
WO2013192225A1 (en) 2013-12-27
IN2015DN00334A (xx) 2015-06-12
US20130338139A1 (en) 2013-12-19
EP2861603B1 (en) 2018-12-19
CN104583217A (zh) 2015-04-29
CA2877146A1 (en) 2013-12-27
JP6240180B2 (ja) 2017-11-29
KR102087756B1 (ko) 2020-03-12
EP2861605A4 (en) 2016-01-13
RU2015100213A (ru) 2016-08-10
US10376514B2 (en) 2019-08-13
CN104583217B (zh) 2017-11-17
AU2013277294A1 (en) 2015-02-05
EP3489238B8 (en) 2022-02-16
US20160075719A1 (en) 2016-03-17
NZ703949A (en) 2016-10-28
US9175010B2 (en) 2015-11-03
RU2015100209A (ru) 2016-08-10
HK1208023A1 (en) 2016-02-19
AU2017272245A1 (en) 2018-01-04
SG10201703253XA (en) 2017-06-29
RU2653054C2 (ru) 2018-05-07
US20170182052A1 (en) 2017-06-29
EP2861605A1 (en) 2015-04-22
US9499562B2 (en) 2016-11-22
WO2013192229A8 (en) 2015-09-03
DK2861603T3 (en) 2019-03-04
US20170209459A1 (en) 2017-07-27
KR20150063030A (ko) 2015-06-08
IN2015DN00335A (xx) 2015-06-12
IL236233A (en) 2016-10-31
US9533996B2 (en) 2017-01-03
KR20150063028A (ko) 2015-06-08
CA2877149C (en) 2021-01-19
CN104583213B (zh) 2018-10-26
CA2877149A1 (en) 2013-12-27
MX2014015737A (es) 2015-09-16
US9284335B2 (en) 2016-03-15
AU2013277298B2 (en) 2017-09-07
AU2017272245B2 (en) 2019-08-29
US20160031901A1 (en) 2016-02-04
AU2013277298A1 (en) 2015-02-05
MX2014015740A (es) 2015-11-06
ES2904267T3 (es) 2022-04-04
CA2877146C (en) 2020-10-20
BR112014031731A2 (pt) 2017-06-27
MX359615B (es) 2018-10-03
CN104583213A (zh) 2015-04-29
EP3489238A1 (en) 2019-05-29
AU2013277294B2 (en) 2017-04-13
US10105367B2 (en) 2018-10-23
KR102191816B1 (ko) 2020-12-17
US20150158885A1 (en) 2015-06-11
RU2659779C2 (ru) 2018-07-04
ES2715325T3 (es) 2019-06-03
JP2015526394A (ja) 2015-09-10
NZ703950A (en) 2016-10-28
IL236233A0 (en) 2015-02-01
BR112014031730B1 (pt) 2023-05-16
BR112014031730A2 (pt) 2017-06-27
EP3489238B1 (en) 2021-10-13

Similar Documents

Publication Publication Date Title
HK1208024A1 (en) Substituted thiophene- and furan-fused azolopyrimidine-5-(6h)-one compounds -5-(6h)-
HK1217946A1 (zh) 司普力西歐他汀類似物
HK1212984A1 (zh) 咪唑並吡啶化合物
HK1248702A1 (zh) 取代的吡咯烷-2-甲酰胺
AP2014007810A0 (en) Imidazopyrrolidinone compounds
HK1200830A1 (en) Substituted pyrrolidine-2-carboxamides -2-
EP2925129A4 (en) PRO-NEUROGENIC COMPOUNDS
EP2887803A4 (en) PRO-NEUROGENIC COMPOUNDS
EP2828262A4 (en) IMIDAZOTRIAZINONVERBINDUNGEN
GB201411223D0 (en) None
HK1206724A1 (en) Substituted benzothienopyrimidines
HK1203933A1 (en) Thienopyrimidine compounds
EP2910004A4 (en) LIMITATION OF MOVEMENT
EP2934541A4 (en) NORIBOGAINE SUBSTITUTE
HK1206022A1 (zh) 取代的咪唑並噠嗪
IL238080A0 (en) Somatostatin-dopamine chimeric analogs
GB201410091D0 (en) None
GB201216512D0 (en) Travel sock
GB201219337D0 (en) Garrods movement
GB201209454D0 (en) Anti-foul attachment
GB201219690D0 (en) New compounds l
GB201206393D0 (en) Use
GB201200317D0 (en) Compounds